European regulators cleared Moderna’s first-of-its-kind vaccine as US approval remains uncertain. On Friday, Moderna’s ...

Moderna said it met with the FDA on Tuesday to discuss the vaccine and afterward, the U.S. regulator accepted a revised ...

In a sudden reversal, the U.S. Food and Drug Administration (FDA) has agreed to review Moderna’s experimental mRNA influenza vaccine.

The World Health Organization (WHO) today announced recommendations for the viral composition of influenza (or "flu") vaccines for the 2026-2027 northern hemisphere influenza season. The announcement ...

With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.

This prompts a reassessment of the stock’s value to determine if this represents a genuine opportunity or a potential trap.

The Food and Drug Administration's about-face comes a little more than a week after the agency refused to consider the ...

The company’s mRNA flu shot, if approved, could be available for the 2026-27 flu season.

The FDA will review Moderna’s new mRNA flu vaccine after reversing course, raising fresh concerns about potential setbacks ...